当前位置: X-MOL 学术Expert Rev. Anticancer Ther. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Current radiotherapy techniques in NSCLC: challenges and potential solutions.
Expert Review of Anticancer Therapy ( IF 3.3 ) Pub Date : 2020-05-13 , DOI: 10.1080/14737140.2020.1760094
Niccolò Giaj-Levra 1 , Paolo Borghetti 2 , Alessio Bruni 3 , Patrizia Ciammella 4 , Francesco Cuccia 1 , Alessandra Fozza 5 , Davide Franceschini 6 , Vieri Scotti 7 , Stefano Vagge 8 , Filippo Alongi 1, 9
Affiliation  

Introduction: Radiotherapy is an important therapeutic strategy in the management of non-small cell lung cancer (NSCLC). In recent decades, technological implementations and the introduction of image guided radiotherapy (IGRT) have significantly increased the accuracy and tolerability of radiation therapy.Area covered: In this review, we provide an overview of technological opportunities and future prospects in NSCLC management.Expert opinion: Stereotactic body radiotherapy (SBRT) is now considered the standard approach in patients ineligible for surgery, while in operable cases, it is still under debate. Additionally, in combination with systemic treatment, SBRT is an innovative option for managing oligometastatic patients and features encouraging initial results in clinical outcomes. To date, in inoperable locally advanced NSCLC, the radical dose prescription has not changed (60 Gy in 30 fractions), despite the median overall survival progressively increasing. These results arise from technological improvements in precisely hitting target treatment volumes and organ at risk sparing, which are associated with better treatment qualities. Finally, for the management of NSCLC, proton and carbon ion therapies and the recent development of MR-Linac are new, intriguing technological approaches under investigation.

中文翻译:

NSCLC当前的放射治疗技术:挑战和潜在解决方案。

简介:放射疗法是治疗非小细胞肺癌(NSCLC)的重要治疗策略。近几十年来,技术实施和影像引导放射疗法(IGRT)的引入极大地提高了放射疗法的准确性和耐受性。研究范围:在本综述中,我们概述了NSCLC管理中的技术机遇和未来前景。 :立体定向放射疗法(SBRT)现在被认为是不适合手术的患者的标准方法,而在可手术病例中,它仍在争论中。此外,与全身治疗相结合,SBRT是治疗少转移患者的一种创新选择,其功能令人鼓舞。迄今为止,在无法使用的本地高级NSCLC中,尽管中位总生存期逐渐增加,但根治性剂量处方并未改变(60 Gy分30次)。这些结果来自精确击中目标治疗量和风险器官的技术改进,这些改进与更好的治疗质量相关。最后,对于NSCLC的管理,质子和碳离子疗法以及MR-Linac的最新发展是新的,令人感兴趣的技术方法。
更新日期:2020-05-13
down
wechat
bug